Navigation Links
Tailor-made Cancer Treatment for Multiple Myeloma Patients Offered by Mayo Clinic

Mayo Clinic Cancer Center, has singled out tumor specific alterations in cellular pathway by which drug bortezomib (Velcade) works.// This drug is administered to patients suffering from multiple myeloma.researchers have identified almost nine genetic mutations in cancer cells that might improve chances of patients responding to the agent.

These findings may help physicians to frame tailor treatment to patients with multiple myeloma, considered to be a cancer that is hard to treat.Multiple Myeloma affects plasma cells of the blood,and is the second most common blood cancer encountered in the United States. "Bortezomib seems to work in about one-third of patients who use it, but we have not been able to predict which ones," says the study's lead author, Leif Bergsagel, M.D., a hematologist at Mayo Clinic Arizona. "We now have identified a group that will likely respond because these nine mutations seem to be present in at least 25 percent of newly diagnosed patients.

"Now that we know the pathway the drug targets, and genetic mutations within this pathway that make patients respond better, we are working on a simple way to select those patients who are the best candidates for use of bortezomib," says Dr. Bergsagel.

In 2003, after only a four-month review, the Food and Drug Administration (FDA) approved use of bortezomib in patients who have failed other treatments for multiple myeloma. Later studies showed it lengthened survival by as much as six months. The drug was the first approved in a new class of agents known as proteasome inhibitors. Proteasomes are large protein groups inside cells that break down other proteins. Agents that inhibit the proteasome cause a buildup of proteins that affect many signaling cascades (various necessary biological processes). Bortezomib was initially thought to exert its activity by disrupting one of two known NF-êB (Nuclear Factor kappa B) pathways which keep cancer cells from self destructing t he first-discovered, or canonical, NF-êB pathway.

But through extensive genetic examination of 42 unique multiple myeloma cell lines and tumor samples taken from 68 patients, the investigators defined multiple genetic mutations in the other NF-êB pathway, the so-called non-canonical pathway. "These mutations make the tumor more dependent on that pathway, and consequently more susceptible to bortezomib treatment," said senior author Rafael Fonseca, M.D., also at Mayo Clinic in Arizona. "Identifying these mutations in patients will help us decide who should be treated with bortezomib, probably as an initial therapy," he says. The researchers are developing a test to check for activation of the non-canonical NF-êB pathway in patients. Now that the mutations have been identified, drug designers may be able to fashion new therapies that are more specific to these genetic alterations and, therefore, less toxic.

Dr. Bergsagel says. "These mutations represent good targets for drug development," he says.



Source-Eurekalert
ST
'"/>




Related medicine news :

1. The Age of Tailor-made Babies
2. Fibroids unlikely to Turn Cancerous
3. Virus Level could Predict Cervical Cancer Risk
4. Cancer Doctors Okays Controversial Prostate Therapy
5. Potential New Cancer Gene Identified
6. Consensus on "Combination Therapy" for Breast Cancer
7. Cancers of Colon & Rectum linked to Cigarette Smoking
8. Life Saving Cancer Drugs – From Chicken! Possible Says Dolly’ Creatos
9. The Cancer Rumour mill working over time
10. Cancer drugs in development nearly doubled since 1995
11. Radioactive Seeds used in Prostate Cancer treatment can migrate with the body
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/26/2016)... ... , ... On Memorial Day, Hope For Heroes and USA Medical ... for the country. The nonprofit Hope For Heroes partnered with the leading provider ... for disabled military veterans, as well as police, firemen, and EMS professionals across the ...
(Date:5/26/2016)... ... 26, 2016 , ... MadgeTech will be showcasing its line of data ... Hampshire at the MadgeTech headquarters. With products sold in more than 100 countries around ... including NASA. , In 2012, NASA strategically set up 17 RHTemp101A MadgeTech ...
(Date:5/26/2016)... ... May 26, 2016 , ... In an effort to provide hair restoration information to the widest ... and those who do not use the app. Dr. Mohebi, the founder of Parsa Mohebi ... Mohebi Live . , Dr. Mohebi says, “The positive response to the Snapchat videos ...
(Date:5/26/2016)... ... 2016 , ... The Lung Institute has partnered with the Gulfcoast ... June 6 at their clinic in downtown Tampa. The class is complimentary for the ... has created a free downloadable 4 Week Smoking Cessation Guide for those ...
(Date:5/26/2016)... ... 26, 2016 , ... The MIAMI Institute for Age Management and Intervention celebrates ... MD, ABAARM. Dr. Adonis , Wellness Physician of the MIAMI Institute is certified ... Institute for Functional Medicine. , He also heads up FITTLab, the comprehensive medical testing ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... , May 25, 2016  According to Kalorama Information, ... billion in 2015.  Though these are challenging times ... opportunity for success for companies that remain optimistic ... of new growth prospects medical device companies spend ... and development (R&D) than do companies in other ...
(Date:5/25/2016)... 25, 2016 Digital Health Dialog, LLC ... by the US Patent and Trademark Office of ... proprietary processes for electronic opt-­in and processing of ... programs, HIPAA compliance and otherwise. Logo - ... "Our technology allows for individuals to ...
(Date:5/24/2016)... 24, 2016 Niederländische Chirurgen ... die es Ärzten erlaubt, ihre Expertise weltweit zu ... kombiniert Live Streaming mit einer Instant-Messaging-Funktion und der ... Mediziner in Europa, Afrika, Asien und den ... die Plattform registriert. Information und Weiterbildung   ...
Breaking Medicine Technology: